JPMorgan Chase & Co. Lowers Danaher (NYSE:DHR) Price Target to $300.00

Danaher (NYSE:DHR) had its price objective dropped by equities researchers at JPMorgan Chase & Co. from $310.00 to $300.00 in a research report issued to clients and investors on Tuesday. The brokerage currently has an “overweight” rating on the conglomerate’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 34.46% from the stock’s previous close.

Several other analysts also recently commented on DHR. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a report on Friday, December 13th. Citigroup cut their target price on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Robert W. Baird lowered their target price on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research note on Tuesday. TD Cowen increased their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Finally, Guggenheim started coverage on Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 target price for the company. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $284.14.

Danaher Price Performance

Shares of NYSE:DHR opened at $223.12 on Tuesday. Danaher has a 1-year low of $223.00 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market capitalization of $161.15 billion, a P/E ratio of 42.58, a P/E/G ratio of 4.43 and a beta of 0.83. The firm’s 50 day simple moving average is $236.09 and its two-hundred day simple moving average is $253.66.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same period last year, the company earned $2.09 earnings per share. Research analysts expect that Danaher will post 7.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Danaher

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Heck Capital Advisors LLC purchased a new stake in shares of Danaher during the 4th quarter valued at $27,000. Decker Retirement Planning Inc. bought a new position in Danaher in the 4th quarter valued at approximately $31,000. Golden State Wealth Management LLC purchased a new stake in Danaher in the fourth quarter worth approximately $31,000. Strategic Financial Concepts LLC bought a new stake in Danaher during the fourth quarter valued at approximately $31,000. Finally, Pineridge Advisors LLC lifted its position in shares of Danaher by 63.3% during the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after buying an additional 57 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.